EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis

Omar Alani, David Wang, Samer Wahood, Sabine Obagi, Diego Dasilva, Matthew J Zirwas, Fabrizio Galimberti, Christopher G Bunick

Journal of Drugs in Dermatology · 2025

DOI: 10.36849/jdd.9049 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von Omar Alani und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cardiovascular Diseases, Heterocyclic Compounds, 3-Ring, Venous Thromboembolism. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin condition associated with risk of cardiovascular disease (CVD), potentially mediated by persistent systemic inflammation. Upadacitinib (UPA), a selective Janus kinase 1 (JAK1) inhibitor, effectively reduces AD-related inflammation and may confer additional cardioprotective and thromboprotective benefits. OBJECTIVE: This review evaluates the incidence of major adverse cardiovascular events (MACE) in patients with AD, comparing background rates reported in the literature to long-term MACE rates observed in clinical trials of UPA. METHODS: A literature review was conducted across PubMed, SCOPUS, and EMBASE to identify studies reporting MACE and venous thromboembolism (VTE) rates in moderate-to-severe AD populations. Long-term (5-year) incidence rates in UPA-treated patients were extracted from clinical trials. Reported background incidence rates in AD populations were included. RESULTS: MACE rates in the background AD populations ranged from 0.3 to 1.2 per 100 patient-years (PY), whereas UPA-treated patients exhibited lower rates (15 mg: 0.2, 30 mg:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicCardiovascular DiseasesHeterocyclic Compounds, 3-RingVenous ThromboembolismHumansIncidenceJanus Kinase 1Chronic DiseaseJanus Kinase Inhibitors

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase 1Janus Kinase Inhibitors

Zitieren

APA

Alani, O., Wang, D., Wahood, S., Obagi, S., Dasilva, D., Zirwas, M. J., Galimberti, F., & Bunick, C. G. (2025). Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.9049

Vancouver

Alani O, Wang D, Wahood S, Obagi S, Dasilva D, Zirwas MJ, et al. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.9049

BibTeX
@article{Alani2025,
  author = {Alani, Omar and Wang, David and Wahood, Samer and Obagi, Sabine and Dasilva, Diego and Zirwas, Matthew J and Galimberti, Fabrizio and Bunick, Christopher G},
  title = {Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis},
  journal = {Journal of Drugs in Dermatology},
  year = {2025},
  doi = {10.36849/jdd.9049}
}
Kostenlos starten →